MedTrace Logo

Fesoterodine "add-on" Male Overactive Bladder Study

NCT00546637 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 947

Last updated 2011-02-18

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy and safety of fesoterodine on overactive bladder symptom improvement when added to ongoing alpha blocker treatment.

Conditions

  • Overactive Bladder Syndrome

Interventions

DRUG

Fesoterodine

Fesoterodine 4mg or 8mg

DRUG

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • United States
  • Belgium
  • Brazil
  • Canada
  • Colombia
  • Germany
  • Greece
  • India
  • Malaysia
  • Netherlands
  • Norway
  • Philippines
  • Poland
  • Singapore
  • Slovakia
  • South Korea
  • Spain
  • Sweden
  • Thailand

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00546637 on ClinicalTrials.gov